Merlin Biosciences News
Most Popular Merlin Biosciences Story
Finding no magic for 'Merlin,' Sir Evans shifts focus
Sir Christopher Evans' is scrapping Merlin Biosciences and transferring the early-stage venture funds to the newly-formed Excalibur, which will shift focus to late-stage therapies. That's bitter... Read more...
Latest Headlines
- April 10, 2008
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
